|1.||Li, Qi-Fu: 7 articles (07/2014 - 02/2006)|
|2.||Shi, Song-Lin: 5 articles (07/2014 - 08/2008)|
|3.||Xu, Dong-Hui: 4 articles (07/2014 - 08/2008)|
|4.||Tang, Jian: 4 articles (12/2010 - 02/2008)|
|5.||Chen, Xiang-Feng: 3 articles (07/2014 - 08/2008)|
|6.||Wu, Fu-Yun: 3 articles (07/2014 - 05/2010)|
|7.||Jing, Guang-Jun: 3 articles (07/2014 - 05/2010)|
|8.||Montano, Monica M: 3 articles (03/2014 - 08/2011)|
|9.||Nalini, Namasivayam: 3 articles (11/2007 - 03/2007)|
|10.||Saravanan, Nadana: 3 articles (11/2007 - 03/2007)|
04/25/2002 - "To investigate the in vitro effect of hexamethylene bisacetamine (HMBA) on the proliferation, cell cycle regulation, and apoptosis of human leukemia cells and to study the relevant mechanisms. "
05/30/1983 - "Friend leukemia cells (FLC) induced to erythroid differentiation by 5 mM hexamethylenebisacetamide (HMBA) are suitable for studies focused on the expression of different genes involved in the same differentiative program. "
04/25/2002 - "In both leukemia cell lines (U937 and K562) lacking wt-p53, a nonapoptotic death pathway may exist during HMBA induction."
04/25/2002 - "After exposure to HMBA for 6 days, the optical absorbance values at 595nm of K562 leukemia cells of the control group and groups with 1, 2, and 4mmol/L HMBA were 1.03, 0.81, 0.58, and 0.36 respectively. "
12/01/2000 - "This JAKs dephosphorylation did not occur in HMBA-resistant clones, suggesting that JAKs are possible targets of the dephosphorylative process required for leukemia cell commitment to differentiation. "
04/01/2001 - "[Study on common character of regulative molecular mechanism of Chinese drug bailong and hexamethylen bisacetamide in human cancer cell cycle and their oncogene and tumor suppressor gene expression]."
04/01/1991 - "A Phase I clinical trial and pharmacological study of nasogastrically administered hexamethylene bisacetamide, a polar-planar compound with in vitro differentiating activity, was conducted in 14 adult patients with refractory cancer. "
12/19/1990 - "Previous phase I trials have demonstrated that HMBA produces hematologic toxicity in morphologically normal bone marrows of patients with solid tumors. "
08/01/1989 - "Clinical trials have shown that HMBA can cause positive therapeutic responses in some cancer patients, but clinical efficacy may be limited, in part, by dose-related toxicity. "
03/01/1989 - "This experimental experience has formed the context for initiating preliminary clinical studies designed to examine the pharmacology of HMBA and to explore its potential for modifying the natural history of cancer."
|3.||Acute Erythroblastic Leukemia (Erythroleukemia)
02/01/2007 - "Proteomic analysis of erythroid differentiation induced by hexamethylene bisacetamide in murine erythroleukemia cells."
07/01/2005 - "clk2, clk3 and clk4), are up-regulated during HMBA-induced erythroleukemia cell differentiation. "
03/01/2002 - "New designed HMBA agents as inducers of erythroleukemia cell differentiation."
02/01/1998 - "Hexamethylenebisacetamide (HMBA) is a potent differentiation inducer of murine erythroleukemia cells. "
10/09/1997 - "During hexamethylene bisactamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells erythroid genes are transcriptionally activated while c-myb and several other nuclear proto-oncogenes are down-regulated. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/15/1992 - "We report results of a phase II clinical trial in 41 patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) to whom HMBA was administered by continuous infusion for 10 days and repeated after an interval of 18 to 75 days. "
11/15/1992 - "Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent."
11/01/2013 - "In the present study, we demonstrated that the combination of baicalin and HMBA synergistically inhibited the proliferation of acute myeloid leukemia (AML) cell lines. "
06/01/1993 - "Clinical studies showed that inducers of differentiation of leukemia cells including retinoic acid, hexamethylene bisacetamide and some chemotherapeutic drugs induced remission in patients with acute myelogenous leukemia. "
10/01/2003 - "Hexamethylene bisacetamide (HMBA) is referred as a differentiation-inducer for the clinical treatment of acute myeloid leukemia and myelodysplastic syndrome. "
|5.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
12/19/1990 - "Although the mechanisms responsible for the antiproliferative effects of HMBA cannot be determined from this study, similar inhibitory effects of HMBA on normal and abnormal hematopoietic progenitors suggest that HMBA may be of limited utility in producing and sustaining elevations of peripheral blood cell counts in patients with myelodysplastic syndrome."
12/19/1990 - "HMBA concentrations that are optimal for differentiation in vitro (2 to 5 mmol/L) and HMBA concentrations that are being achieved in clinical trials (1 to 2 mmol/L) inhibited the growth of granulocyte-macrophage colony-forming units and erythroid burst-forming units from all 15 patients with myelodysplastic syndrome and all 4 normal subjects, HMBA did not induce proliferation of myelodysplastic or normal progenitors at any concentration; rather, it produced nearly identical inhibition of normal and myelodysplastic hematopoietic progenitors. "
06/01/1992 - "Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations."
12/19/1990 - "Because of concern that HMBA may produce more severe myelotoxicity in patients with myelodysplastic syndrome since these patients have limited hematopoietic reserves, we studied the effects of HMBA on myelodysplastic and normal hematopoietic progenitors in vitro. "
12/19/1990 - "HMBA is currently being studied in patients with myelodysplastic syndrome. "
|1.||hexamethylene bisacetamide (HMBA)
|2.||Dimethyl Sulfoxide (DMSO)
|3.||Tretinoin (Retinoic Acid)
|9.||Messenger RNA (mRNA)
|10.||Protein Kinase C